Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 4/20 | 0.41 |
| ▸ | JAK3 | P52333 | 4/20 | 0.41 |
| ▸ | BRAF | P15056 | 6/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17047483 | 0.84 | PIK3CG (0.50) | PIK3CAPIK3CGPIK3CDBRAFDGAT1 | |
| SCHEMBL17047522 | 0.83 | PIK3CG (0.59) | PIK3CAPIK3CGPIK3CDBRAFDGAT1 | |
| SCHEMBL17047502 | 0.82 | PIK3CA (0.47) | PIK3CAPIK3CGPIK3CDBRAFDGAT1 | |
| SCHEMBL18382203 | 0.80 | RET (0.54) | PIK3CAPIK3CGPIK3CDPIK3CBRET | |
| SCHEMBL17047460 | 0.80 | PIK3CG (0.70) | PIK3CAPIK3CGPIK3CDBRAFPIK3CB | |
| SCHEMBL7153086 | 0.79 | ROCK1 (0.47) | PIK3CAPIK3CGPIK3CDABCB1ABCG2 | |
| SCHEMBL17047464 | 0.78 | PIK3CA (0.69) | PIK3CAPIK3CGPIK3CDBRAFPIK3CB | |
| SCHEMBL17047475 | 0.78 | IKBKB (0.44) | PIK3CAPIK3CGPIK3CDBRAFDGAT1 | |
| SCHEMBL17047495 | 0.78 | BRAF (0.63) | PIK3CAPIK3CGBRAF | |
| SCHEMBL17047571 | 0.77 | PIK3CG (0.52) | PIK3CAPIK3CGPIK3CDBRAFDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202374-B2 | 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-02-12 | — | — | US | disclosed |
| EP-3110801-B1 | 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS | COUNCIL SCIENT IND RES (IN) | 2019-01-30 | — | — | EP | disclosed |
| US-20170015662-A1 | 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-01-19 | — | — | US | disclosed |
| EP-3110801-A1 | 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015128873-A1 | \"6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS\ | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202374-B2 | 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors | PIK3CA, PI4KA, PDPK1 | PIK3CA 1/4885PIK3CG 5/4885PIK3CD 4/4885 |
| US-20170015662-A1 | 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS | PIK3CA, PI4KA, PDPK1 | PIK3CA 1/4885PIK3CG 5/4885PIK3CD 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.